Novo Nordisk A/S: Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders
Bagsværd, Denmark and Watertown, Mass, US, 01 September 2022 - Novo Nordisk and Forma Therapeutics, Holdings Inc. (Nasdaq: FMTX) today announced that they have entered into a definitive agreement under